5. References

  1. Fentanyl citrate oral transmucosal lozenge (Actiq®) package insert. Cephalon, Inc. March 2021.
  2. Fentanyl buccal tablet (Fentora®) package insert. Cephalon, Inc. March 2021.
  3. Fentanyl sublingual tablets (Abstral®) package insert. Sentynl Therapeutics, Inc., December 2019.
  4. Fentanyl sublingual spray (Subsys®) package insert. Insys Therapeutics, Inc., May 2021.
  5. Fentanyl nasal spray (Lazanda®) package insert. West Therapeutic Development, LLC, March 2021.
  6. Fentanyl transdermal system (Duragesic®) package insert. Janssen Pharmaceuticals, Inc., July 2021.
  7. DRUGDEX® System (electronic version). Truven Health Analytics, Greenwood Village, Colorado, USA. Available at: http://www.micromedexsolutions.com.libproxy.uthscsa.edu/. Accessed November 18, 2021.
  8. Clinical Pharmacology [database online]. Tampa, FL: Gold Standard, Inc.; 2021. Available at: http://www.clinicalpharmacology-ip.com.ezproxy.lib.utexas.edu/. Accessed November 18, 2021.
  9. Facts and Comparisons eAnswers [database online]. Hudson, Ohio: Wolters Kluwer Clinical Drug Information, Inc.; 2021. Available at: https://fco-factsandcomparisons-com.ezproxy.lib.utexas.edu. Accessed November 18, 2021. 
  10. American Society of Health-System Pharmacists. 2021. AHFS Drug Information® - 2021st Ed. Bethesda, MD. American Society of Health-System Pharmacists®. STAT!Ref Online Electronic Medical Library. Available at: https://online.statref.com/document/cQfe8yqMRNqgSGqm4Qo8Qj. Accessed November 18, 2021.
  11. Lexicomp Online, Lexi-Drugs Online, Hudson, Ohio: Wolters Kluwer Clinical Drug Information, Inc.; 2021; November 18, 2021.
  12. Christie JM, Simmonds M, Patt R, et al. Dose-titration, multicenter study of oral transmucosal fentanyl citrate for the treatment of breakthrough pain in cancer patients using transdermal fentanyl for persistent pain. J Clin Oncol. 1998;16:3238-45.
  13. Mystakidou K, Katsouda E, Parpa E, Tsiatas ML, Vlahos L. Oral transmucosal fentanyl citrate for the treatment of breakthrough pain in cancer patients:  an overview of its pharmacological and clinical characteristics. Am J Hosp Palliat Care. 2005;22:228-32.
  14. Coluzzi PH, Schwartzberg L, Conroy JD, et al. Breakthrough cancer pain: a randomized trial comparing oral transmucosal fentanyl citrate (OTFC) and morphine sulfate immediate release (MSIR). Pain. 2001;91:123-30.
  15. Burton AW, Drive LC, Mendoza TR, Syed G. Oral transmucosal fentanyl citrate in the outpatient management of severe cancer pain crises. A retrospective case series. Clin J Pain. 2004;20:195-7.
  16. CDC guideline for prescribing opioids for chronic pain — united states, 2016. MMWR Recomm Rep. 2016;65.
  17. Oral transmucosal fentanyl citrate used to reduce emergency department visits in migraine patients: a prospective open label trial. [abstract]. Pain Medicine. 2003:4:104. Abstract no. 536
  18. Landy SH. Oral transmucosal fentanyl citrate for the treatment of migraine headache pain in outpatients: a case series. Headache. 2004;44:762-6.
  19. Brandow AM, Carroll CP, Creary S, et al. American Society of Hematology 2020 guidelines for sickle cell disease: management of acute and chronic pain. Blood Adv. 2020;4(12):2656-2701.
  20. Binstock W, Rubin R, Bachman C, et al. The effect of premedication with OTFC, with or without ondansetron, on postoperative agitation and nausea and vomiting in pediatric ambulatory patients. Paediatr Anaesth. 2004;14:759-67.
  21. Dsida RM, Wheeler M, Birmingham PK, et al. Premedication of pediatric tonsillectomy patients with oral transmucosal fentanyl citrate. Anesth Analg. 1998;86:66-70.
  22. Epstein RH, Mendel HG, Witkowski TA, et al. The safety and efficacy of oral transmucosal fentanyl citrate for preoperative sedation in young children.  Anesth Analg. 1996;83:1200-5.
  23. Howell, TK, Smith S, Rushman SC, et al. A comparison of oral transmucosal fentanyl and oral midazolam for premedication in children. Anaesthesia. 2002;57:798-805.
  24. Mahar PJ, Rana JA, Kennedy CS, et al. A randomized clinical trial of oral transmucosal fentanyl citrate versus intravenous morphine sulfate for initial control of pain in children with extremity injuries. Pediatr Emerg Care. 2007;23:544-8.
  25. Robert R, Brack A, Blakeney P, et al. A double-blind study of the analgesic efficacy of oral transmucosal fentanyl citrate and oral morphine in pediatric patients undergoing burn dressing change and tubbing. J Burn Care Rehabil. 2003;24:351-355.
  26. Schechter NL, Weisman SJ, Rosenblum M, et al. The use of oral transmucosal fentanyl citrate for painful procedures in children. Pediatrics. 1995;95:335-9.
  27. Sharar SR, Bratton SL, Carrougher GJ, et al. A comparison of transmucosal fentanyl citrate and oral hydromorphone for inpatient pediatric burn wound care analgesia. J Burn Care Rehabil. 1998;19:516-21.
  28. Sharar SR, Carrougher GJ, Selzer K, et al. A comparison of oral transmucosal fentanyl citrate and oral oxycodone for pediatric outpatient wound care. J Burn Care Rehabil. 2002;23:27-31.
  29. Mudd S. Intranasal fentanyl for pain management in children: a systematic review of the literature. J Pediatr Health Care. 2011;25:316-322.
  30. Naloxone hydrochloride (Narcan®) 4 mg/ 0.1 mL nasal spray package insert. Emergent Devices Inc., March 25, 2021. 
  31. Naloxone hydrochloride (Kloxxado®) 8 mg/ 0.1 mL nasal spray package insert. Hikma Specialty USA Inc., April 2021.
  32. Naloxone hydrochloride (Evzio®) 0.4 mg/ 0.4 mL pre-filled syringe autoinjector package insert. HF Acquisition Co LLC, DBA HealthFirst, February 2020.
  33. Naloxone hydrochloride (LifEMS®) 2 mg/ 2 mL solution for injection convenience kit package insert. Lifsa Drugs LLC, November 2020.
  34. U.S. Food and Drug Administration. FDA recommends health care professionals discuss naloxone with all patients when prescribing opioid pain relievers or medicines to treat opioid use disorder. FDA Drug Safety Communication. Published online July 23, 2020. Available at: https://www.fda.gov/drugs/drug-safety-and-availability/fda-recommends-health-care-professionals-discuss-naloxone-all-patients-when-prescribing-opioid-pain. Accessed November 19th, 2021.
  35. Texas Pharmacy Association. Texas pharmacist naloxone standing order application. October 2016. Available at: https://www.texaspharmacy.org/page/TXPHARMNALOX. Accessed November 19th, 2021.
  36. Turkel SB, Nadala JGB, Wincor MZ. Possible serotonin syndrome in association with 5-HT3 antagonist agents. Psychosomatics. 2001;42:258-260.